It may be useful to group patients with atypical chronic myeloid leukemia (aCML) into certain risk categories, according to a study involving 25 individuals.
Participants—all with aCML—were a median of 70 years of age. All had gene mutations, and more than one-third had cytogenetic abnormalities. Among the results:
- Median overall survival was ~11 months.
- At a median follow-up of 11 months, 68% had died, and 8% experienced leukemic transformations.
- Survival was adversely impacted by advanced age; low hemoglobin; red blood cell transfusion dependence; high white blood cell count; TET2, NRAS, PTPN11 mutations; and the presence of ≥3 gene mutations.
- In multivariable analysis, age >67; low hemoglobin; and TET2 mutations retained prognostic significance.
Patnaik M, Barraco D, Lasho T, et al. Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. Am J Hematol. 2017;92(6):542-548. doi:10.1002/ajh.24722.
This Week's Must Reads
Must Reads in Hematologic Malignancies
Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10
Prognostic Score System for Patients with PMF, J Clin Oncol; ePub 2017 Dec 9; Gugliemelli, et al
These Patients Are More Apt to Be Depressed, Ann Hematol; ePub 2017 Dec 7; Shreders, et al
Survival Length Shortest in These Patients with MF, Eur J Haematol; ePub 2017 Dec 11; Masarova, et al
The Value of Ruxolitinib Before and After AlloSCT, Blood; ePub 2017 Dec 7; Poulose, Malysz, et al